Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ABVC BioPharma, Inc. - Common Stock (NQ:ABVC)

0.9803 +0.0103 (+1.06%)
Streaming Delayed Price Updated: 1:03 PM EDT, Sep 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 30,754
Open 0.9200
Bid (Size) 0.9670 (100)
Ask (Size) 0.9801 (500)
Prev. Close 0.9700
Today's Range 0.9005 - 0.9971
52wk Range 0.7069 - 3.400
Shares Outstanding 23,541,824
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
These stocks that are showing activity before the opening bell on Thursday. ↗
Via Chartmill
Which stocks are experiencing notable movement on Thursday? ↗
Via Chartmill

Performance

YTD
-55.2%
-55.2%
1 Month
+3.2%
+3.2%
3 Month
-24.0%
-24.0%
6 Month
-31.0%
-31.0%
1 Year
-64.4%
-64.4%

More News

Read More
News headline image
ABVC BioPharma, Inc. Announces Planned Spin-Off of BioKey (Cayman), Inc. Through Dividend Distribution of BioKey Shares to ABVC Shareholders
Via NewMediaWire
Topics Artificial Intelligence
ABVC BioPharma Reports 2025 Form 10-K
Via TheNewswire.com
ABVC BioPharma, Inc. Announces Planned Spin-Off of BioKey (Cayman), Inc. Through Dividend Distribution of BioKey Shares to ABVC Shareholders
Via TheNewswire.com
Topics Artificial Intelligence
News headline image
ABVC BioPharma Reports 2025 Form 10-K
Via NewMediaWire
News headline image
ABVC BioPharma Provides Corporate and Structural Update
Via NewMediaWire
Topics Intellectual Property
ABVC BioPharma Provides Corporate and Structural Update
Via TheNewswire.com
Topics Intellectual Property
News headline image
ABVC BioPharma Highlights Safety Profile of Its Plant-Based ADHD Candidate Amid Growing Concerns About Psychiatric Polypharmacy in the United States
Via NewMediaWire
ABVC BioPharma Highlights Safety Profile of Its Plant-Based ADHD Candidate Amid Growing Concerns About Psychiatric Polypharmacy in the United States
Via TheNewswire.com
News headline image
ABVC BioPharma Highlights Strengthened Operations at BioKey's 28,176-sq.-ft. Silicon Valley Facility, Featuring U.S.-Based Multi-Product Capabilities Including Functional Foods, and Expansion Outlook Supporting Up to [1,000] Jobs by 2030
Via NewMediaWire
ABVC BioPharma Highlights Strengthened Operations at BioKey's 28,176-sq.-ft. Silicon Valley Facility, Featuring U.S.-Based Multi-Product Capabilities Including Functional Foods, and Expansion Outlook Supporting Up to [1,000] Jobs by 2030
Via TheNewswire.com
News headline image
ABVC Receives US$250,000 From ForSeeCon; Vitargus(R) Total Licensing Fee up to US$33.5 Million; US$816,000 Already Received
Via NewMediaWire
ABVC Receives US$250,000 From ForSeeCon; Vitargus(R) Total Licensing Fee up to US$33.5 Million; US$816,000 Already Received
Via TheNewswire.com
News headline image
ABVC BioPharma Receives US$240,000 Licensing Payment From OncoX BioPharma; Total Licensing Payments Reach Approximately US$2.53 Million
Via NewMediaWire
Topics Artificial Intelligence
ABVC BioPharma Receives US$240,000 Licensing Payment From OncoX BioPharma; Total Licensing Payments Reach Approximately US$2.53 Million
Via TheNewswire.com
Topics Artificial Intelligence
News headline image
ABVC BioPharma Reports 230% YoY Licensing Revenue Growth and 181% Asset Expansion in Q3 2025
Via NewMediaWire
News headline image
ABVC BioPharma Reports 230% YoY Licensing Revenue Growth and 181% Asset Expansion in Q3 2025
Via TheNewswire.com
News headline image
ABVC BioPharma Receives Additional US$100,000 Licensing Payment from OncoX BioPharma, Bringing Total Payments to US$695,950
Via NewMediaWire
News headline image
ABVC BioPharma Receives Additional US$100,000 Licensing Payment from OncoX BioPharma, Bringing Total Payments to US$695,950
Via TheNewswire.com
ABVC BioPharma Highlighted by U.S. Financial Media as One of the Best Biotech Investments; Q3 Licensing Revenue Reaches $1.27 Million, With Clear Clinical Progress Across CNS and Oncology
Via TheNewswire.com
News headline image
ABVC BioPharma Highlighted by U.S. Financial Media as One of the Best Biotech Investments; Q3 Licensing Revenue Reaches $1.27 Million, With Clear Clinical Progress Across CNS and Oncology
Via NewMediaWire
News headline image
ABVC BioPharma Has Received a Cumulative Total of US$566,000 Under ForSeeCon Licensing Agreement Supporting GMP Facility in Hsinchu for Vitargus(R) Production
Via NewMediaWire
ABVC BioPharma Has Received a Cumulative Total of US$566,000 Under ForSeeCon Licensing Agreement Supporting GMP Facility in Hsinchu for Vitargus(R) Production
Via TheNewswire.com
ABVC BioPharma Reports US$1.03 Million in Total Licensing Revenues Collected in Q3 to Date, Highlighting High-Margin Business Model
Via TheNewswire.com

Frequently Asked Questions

Is ABVC BioPharma, Inc. - Common Stock publicly traded?
Yes, ABVC BioPharma, Inc. - Common Stock is publicly traded.
What exchange does ABVC BioPharma, Inc. - Common Stock trade on?
ABVC BioPharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ABVC BioPharma, Inc. - Common Stock?
The ticker symbol for ABVC BioPharma, Inc. - Common Stock is ABVC on the Nasdaq Stock Market
What is the current price of ABVC BioPharma, Inc. - Common Stock?
The current price of ABVC BioPharma, Inc. - Common Stock is 0.9803
When was ABVC BioPharma, Inc. - Common Stock last traded?
The last trade of ABVC BioPharma, Inc. - Common Stock was at 09/10/26 01:03 PM ET
What is the market capitalization of ABVC BioPharma, Inc. - Common Stock?
The market capitalization of ABVC BioPharma, Inc. - Common Stock is 23.08M
How many shares of ABVC BioPharma, Inc. - Common Stock are outstanding?
ABVC BioPharma, Inc. - Common Stock has 23M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.